Senators Push GlaxoSmithKline to Overcome Shingrix Shortage

July 10, 2018

Two U.S. senators have urged manufacturer GlaxoSmithKline (GSK) to do more to overcome shortages of the highly demanded Shingrix® vaccine, according to a July 6 FiercePharma report.

Shingrix, the CDC-recommended and newly approved shingles vaccine, faces such high demand that healthcare providers are running out of it.

The Centers for Disease Control and Prevention (CDC) announced shortages in May and said that the delays and ordering limits would last through June of next year. As of May, more than 1.5 million people had received the vaccine.

On June 29, Senators Amy Klobuchar and Tina Smith urged GSK to “take every necessary action to alleviate the shortage of its shingles vaccine.”

The senators wrote that patients may not be able to complete their recommended schedule of two doses in six months, FiercePharma reported. In an update with CBS in Minnesota, Sen. Klobuchar said GSK responded quickly and plans to meet with her.